Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026)

Ardelyx (ARDX) posted Total Non-Current Liabilities of $330.0 million for Q1 2026, up 6.88% on a QoQ basis from $308.8 million in Q4 2025, and up 38.67% year-over-year from $238.0 million in Q1 2025.

Ardelyx (ARDX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends

Ardelyx's Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $330.0 million for Q1 2026.

  • Quarterly Total Non-Current Liabilities rose 38.67% year-over-year to $330.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $330.0 million (up 38.67% YoY) and the FY2025 annual result came in at $308.8 million, up 30.32% from the prior year.
  • Total Non-Current Liabilities was $330.0 million for Q1 2026 at Ardelyx, up from $308.8 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $330.0 million in Q1 2026 and bottomed at $67.4 million in Q3 2022.
  • A 5-year average of $176.5 million and a median of $171.5 million in 2024 frame the typical range for Total Non-Current Liabilities.
  • Annual changes were most pronounced in 2023 — Total Non-Current Liabilities gained 8.52% — and 2024, when it surged 131.65%.
  • Ardelyx's Total Non-Current Liabilities stood at $80.5 million in 2022, then soared by 37.4% to $110.6 million in 2023, then surged by 114.26% to $236.9 million in 2024, then surged by 30.32% to $308.8 million in 2025, then increased by 6.88% to $330.0 million in 2026.
  • Business Quant data shows ARDX's Total Non-Current Liabilities at $330.0 million in Q1 2026, $308.8 million in Q4 2025, and $303.3 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 4.45 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - 110.28 Mn
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 1.98 Bn
4 NuCana 279.75 Bn 279.75 Bn - 949,738.67
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 5.87 Bn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn 7.32 Bn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 40.00 Mn
9 Revolution Medicines 37.78 Bn 37.78 Bn - 746.94 Mn
10 Ardelyx 1.26 Bn 1.02 Bn 89.66 Mn 330.02 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 330.02 Mn
Dec 31, 2025 308.78 Mn
Sep 30, 2025 303.26 Mn
Jun 30, 2025 299.48 Mn
Mar 31, 2025 238.00 Mn
Dec 31, 2024 236.94 Mn
Sep 30, 2024 185.19 Mn
Jun 30, 2024 173.39 Mn
Mar 31, 2024 169.61 Mn
Dec 31, 2023 110.58 Mn
Sep 30, 2023 98.05 Mn
Jun 30, 2023 74.85 Mn
Mar 31, 2023 79.38 Mn
Dec 31, 2022 80.48 Mn
Sep 30, 2022 67.39 Mn
Jun 30, 2022 68.98 Mn
Dec 31, 2021 67.30 Mn
Dec 31, 2020 74.07 Mn
Sep 30, 2020 65.96 Mn
Jun 30, 2020 69.87 Mn